Saturday, April 21, 2018

Goldman Sachs Analysts Question Whether Curing Patients Is Good for Business

Goldman Sachs Analysts Question Whether Curing Patients Is Good for Business:
Image result for miracle cure"“Is curing patients a sustainable business model?” analysts asked in an April 10 report entitled “The Genome Revolution,” which CNBC first reported.
One-and-done cures enabled by gene editing, analyst Salveen Richter wrote in the note to clients this week, are near-miraculous innovations that stand to benefit patients immensely.
But they also present a challenge to business.
“While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow,” she wrote.
The trouble is, it’s hard to reap long-term profits when you’re actually curing the patients who would buy your treatment..."
Read all!

No comments: